Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances ...

Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical ...

Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend ...

Kiniksa is shifting to next-gen IL-1 antibodies for recurrent pericarditis. Click here to read more on how this impacts KNSA stock in 2025 and beyond.

We recently compiled a list of the 10 Best UK Growth Stocks to Buy Now. In this article, we are going to take a look at where ...

Wells Fargo lowered the firm’s price target on Kiniksa (KNSA) to $30 from $35 and keeps an Overweight rating on the shares. While abiprubart’s ...

Kiniksa (KNSA) plans to discontinue the development of abiprubart in Sjogren’s Disease. The company will explore strategic alternatives for the asset. Kiniksa has exercised its right to ...

Kiniksa Pharmaceuticals International reported significant financial results for Q4 and full year 2024, with ARCALYST® (rilonacept) net product revenues reaching $122.5 million for Q4 and $417 ...

Reports Q4 revenue $122.5M, consensus $123.38M. “Strong commercial execution in 2024 resulted in 79% year-over-year ARCALYST sales growth to ...

Y Intercept Hong Kong Ltd acquired a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) in the 4th ...

Patel, Chairman and Chief Executive Officer of Kiniksa. “Today, we are excited to announce the development program for KPL-387, which we believe could expand the treatment options for recurrent ...